Ensysce Biosciences Reports Decrease in Revenue and Increased Net Loss in Latest 10-Q Filing

Ensysce Biosciences, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated $1.16 million in revenue from federal grants during the quarter, a decrease from $1.37 million in the same period last year. For the six months ending June 30, 2026, total revenue from grants was $2.13 million, down from $2.69 million in the prior year. The decline in revenue is attributed to the timing of research activities eligible for funding under the MPAR grant. Ensysce's operating expenses increased to $3.74 million for the quarter, compared to $3.12 million in the previous year, primarily driven by higher research and development costs associated with increased clinical activity for its lead product candidate, PF614.

The company reported a net loss of $2.57 million for the three months ended June 30, 2026, compared to a net loss of $1.73 million for the same period in 2025. For the six-month period, the net loss widened to $6.13 million from $3.68 million in the prior year. The increase in losses is largely due to rising operating expenses, particularly in research and development, which totaled $5.82 million for the first half of 2026, up from $3.81 million in 2025. General and administrative expenses slightly decreased to $2.45 million from $2.60 million year-over-year.

In terms of strategic developments, Ensysce completed the acquisition of Cy Biopharma, Inc. on August 5, 2026. This acquisition is expected to enhance Ensysce's capabilities in developing therapies for chronic pain, particularly its lead product candidate for Complex Regional Pain Syndrome, which has received Orphan Drug Designation from the FDA. The acquisition was financed through a private placement that raised approximately $21.5 million, with potential additional funding of up to $38.6 million contingent on achieving specific clinical milestones.

As of June 30, 2026, Ensysce had $676,704 in cash and cash equivalents, a significant decrease from $4.31 million at the end of 2025. The company anticipates that its existing cash resources will be sufficient to fund operations through late third quarter 2026, raising concerns about its ability to continue as a going concern without additional capital. Ensysce plans to finance its operations through a combination of equity offerings, debt financing, and potential collaborations, although it acknowledges the uncertainty surrounding the availability of such funding.

Looking ahead, Ensysce expects to continue incurring substantial expenses related to the development and potential commercialization of its product candidates. The company is focused on advancing its clinical trials and expanding its product pipeline, but it remains uncertain about the timing and costs associated with these efforts. The management has indicated that the ability to raise additional capital will be critical to sustaining operations and achieving its strategic objectives.